Active	Status	Sponsor type	Region	Phase	Filter
1 Active 4 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
triciribine phosphate (PTX-200) / VioQuest, Prescient Therap
NCT02930109: A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia Jul 2019 - Sep 2019 : From P1b portion of P1b/2 trial	Completed	1/2	33	US	PTX-200, Triciribine Phosphate Monohydrate, Cytarabine, Ara-C	Prescient Therapeutics, Ltd.	Acute Leukemia	10/23	03/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
triciribine phosphate (PTX-200) / VioQuest, Prescient Therap
NCT02930109: A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia Jul 2019 - Sep 2019 : From P1b portion of P1b/2 trial	Completed	1/2	33	US	PTX-200, Triciribine Phosphate Monohydrate, Cytarabine, Ara-C	Prescient Therapeutics, Ltd.	Acute Leukemia	10/23	03/24